In the randomized phase II Austrian Breast and Colorectal Cancer Study Group (ABCSG) 34 trial, the efficacy of a mucin-1 (MUC1) vaccination in combination with neoadjuvant treatment was tested in HER2-negative breast cancer patients. Here, ERBB2 is linked to breast carcinoma.